Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.

1st Quarter 2026:

• Sales of €72.9 million (previous year: €68.2 million)
• EBIT before special items of €16.0 million (previous year: €16.2 million)
• Net income of €10.4 Mio.  (previous year: €9.7 million)

 Forecast 2026:

• Sales of around €320 million (confirmed)
• EBIT before special items of around €80 million (confirmed)  

Berlin, 12 May 2026. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year. Due to a slightly weaker product mix in the Isotope Products segment during the first two months of the year, adjusted Group EBIT decreased by 2% to €16.0 million. Net income increased by 7% to €10.4 million, or €0.17 per share.

Sales in the Medical segment were significantly higher in the first three months of the year at €41.5 million compared to the previous year (€34.4 million). The pharmaceutical radioisotope business remains the most important revenue driver. In particular, the development of sales of generators and in the Contract Manufacturing & Development (CDMO) segment is worth noting.

The Isotope Products segment generated sales of €31.5 million, which was €2.3 million, or approximately 7%, lower than in the first three months of the previous year. A strong fourth quarter of 2025 was followed by a subdued start to the year, which regained significant momentum in March.

The forecast for fiscal year 2026, published on 26 March 2026, remains unchanged. The Executive Board continues to anticipate revenue of approximately €320 million and adjusted EBIT of approximately €80 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q12026en

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler SE
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com